isavuconazole and Communicable-Diseases--Emerging

isavuconazole has been researched along with Communicable-Diseases--Emerging* in 1 studies

Other Studies

1 other study(ies) available for isavuconazole and Communicable-Diseases--Emerging

Article	Year
Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. Journal of clinical microbiology, 2013, Volume: 51, Issue:9 Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya udagawae and yeast Cryptococcus gattii VGII (implicated in the outbreak in the Pacific Northwest, North America) exhibit reduced susceptibilities to several azoles but higher susceptibilities to isavuconazole. Topics: Antifungal Agents; Aspergillus; Azoles; Communicable Diseases, Emerging; Cryptococcus gattii; Humans; Microbial Sensitivity Tests; Mycoses; Neosartorya; Nitriles; North America; Pyridines; Triazoles	2013

Article

Year

Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Journal of clinical microbiology, 2013, Volume: 51, Issue:9

Isavuconazole is an extended-spectrum triazole with in vitro activity against a wide variety of fungal pathogens. Clinical isolates of molds Aspergillus lentulus and Neosartorya udagawae and yeast Cryptococcus gattii VGII (implicated in the outbreak in the Pacific Northwest, North America) exhibit reduced susceptibilities to several azoles but higher susceptibilities to isavuconazole.

Topics: Antifungal Agents; Aspergillus; Azoles; Communicable Diseases, Emerging; Cryptococcus gattii; Humans; Microbial Sensitivity Tests; Mycoses; Neosartorya; Nitriles; North America; Pyridines; Triazoles

2013